Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 16/20 | 0.76 |
| ▸ | HDAC2 | Q92769 | 13/20 | 0.76 |
| ▸ | HDAC3 | O15379 | 9/20 | 0.76 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.76 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.76 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.76 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.76 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.76 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.76 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.76 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.76 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29603842 | 1.00 | HDAC1 (0.76) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL6243828 | 0.91 | HDAC1 (0.76) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| Hydrochloric Acid SCHEMBL1435432 | 0.90 | HDAC1 (0.74) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL2410081 | 0.90 | HDAC1 (0.78) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| Hydrochloric Acid SCHEMBL2418342 | 0.88 | HDAC1 (0.71) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL673383 | 0.87 | HDAC1 (1.00) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| Hydrochloric Acid SCHEMBL2413482 | 0.87 | HDAC1 (0.68) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL6077129 | 0.85 | HDAC1 (0.81) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL30091870 | 0.85 | HDAC1 (0.74) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL2412920 | 0.84 | HDAC1 (0.76) | HDAC1HDAC2HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023242070-A9 | ANTIMICROBIAL COMPOUNDS | AKTHELIA PHARMACEUTICALS (IS) | 2024-06-20 | — | — | WO | claimed |
| WO-2023242070-A1 | ANTIMICROBIAL COMPOUNDS | AKTHELIA PHARMACEUTICALS (IS) | 2023-12-21 | — | — | WO | claimed |
| EP-3062784-B1 | ANTIMICROBIAL COMPOUNDS | AKTHELIA PHARMACEUTICALS (IS) | 2020-12-23 | — | — | EP | claimed |
| CN-110446504-A | With the antibody combined epigenetic modulators for treatment cancer of brain signal protein-4 D | VACCINEX INC | 2019-11-12 | — | — | CN | claimed |
| US-9957226-B2 | Antimicrobial compounds | AKTHELIA PHARMACEUTICALS (IS) | 2018-05-01 | — | — | US | claimed |
| US-20160257642-A1 | ANTIMICROBIAL COMPOUNDS | AKTHELIA PHARMACEUTICALS (IS) | 2016-09-08 | — | — | US | claimed |
| EP-3062784-A1 | ANTIMICROBIAL COMPOUNDS | Akthelia Pharmaceuticals (IS) | 2016-09-07 | — | — | EP | claimed |
| CN-105682655-A | Antimicrobial compounds | 阿克塞利亚制药公司 | 2016-06-15 | — | — | CN | claimed |
| WO-2015063694-A1 | ANTIMICROBIAL COMPOUNDS | AKTHELIA PHARMACEUTICALS (IS) | 2015-05-07 | — | — | WO | claimed |
| US-9000031-B2 | Thioxanthone-based autophagy inhibitor therapies to treat cancer | SPECTRUM PHARMACEUTICALS, INC. (US) | 2015-04-07 | — | — | US | claimed |
| US-8524762-B2 | Thioxanthone-based autophagy inhibitor therapies to treat cancer | SPECTRUM PHARMACEUTICALS, INC. (US) | 2013-09-03 | — | — | US | claimed |
| EP-2544673-A1 | THIOXANTHONE-BASED AUTOPHAGY INHIBITOR THERAPIES TO TREAT CANCER | Spectrum Pharmaceuticals, Inc. (US) | 2013-01-16 | — | — | EP | claimed |
| US-20110275696-A1 | Thioxanthone-Based Autophagy Inhibitor Therapies to Treat Cancer | SPECTRUM PHARMACEUTICALS, INC. | 2011-11-10 | — | — | US | claimed |
| WO-2011112623-A1 | THIOXANTHONE-BASED AUTOPHAGY INHIBITOR THERAPIES TO TREAT CANCER | SPECTRUM PHARMACEUTICALS, INC. (US) | 2011-09-15 | — | — | WO | claimed |
| WO-2023242070-A9 | ANTIMICROBIAL COMPOUNDS | AKTHELIA PHARMACEUTICALS (IS) | 2024-06-20 | — | — | WO | disclosed |
| US-20240173320-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | Epizyme, Inc. | 2024-05-30 | — | — | US | disclosed |
| WO-2023242070-A1 | ANTIMICROBIAL COMPOUNDS | AKTHELIA PHARMACEUTICALS (IS) | 2023-12-21 | — | — | WO | disclosed |
| US-20100152188-A1 | Novel Heterocyclic Compounds | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-06-17 | — | — | US | disclosed |
| WO-2008124699-A1 | A METHOD OF USING PROTEASOME INHIBITORS IN COMBINATION WITH HISTONE DEACETYLASE INHIBITORS TO TREAT CANCER | NEREUS PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2007017728-A2 | NOVEL HETEROCYCLIC COMPOUNDS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240173320-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | EHMT2, BHMT2, BHMT | HDAC1 1120/4885HDAC2 268/4885HDAC3 1170/4885 |
| US-20100152188-A1 | Novel Heterocyclic Compounds | CYP11B2, CYP3A5, CYP11B1 | HDAC1 307/4885HDAC2 642/4885HDAC3 255/4885 |
| US-20160257642-A1 | ANTIMICROBIAL COMPOUNDS | BECN1, SQSTM1, ATG7 | HDAC1 16/4885HDAC2 23/4885HDAC3 4/4885 |
| US-20110275696-A1 | Thioxanthone-Based Autophagy Inhibitor Therapies to Treat Cancer | ATG7, BECN1, SQSTM1 | HDAC1 464/4885HDAC2 929/4885HDAC3 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.